Search all trials

Find therapies in clinical trials near you – page 46

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 968
countries: 28
conditions: 2 103

3 968 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Colorectal cancer

Not recruiting

Registered drugNo placebo

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo

Norway

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Elranatamab

Contact Research Centre

Malignant melanoma+1

Not recruiting

Registered drugNo placebo

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo

Norway

Participants:0–17 years · 18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Cardiovascular disorder+1

Not recruiting

InvestigationalNo placebo

Study on Long-Term Effects of Lerodalcibep for Lowering Cholesterol in Patients with Familial Hypercholesterolemia or Cardiovascular Disease Risks

InvestigationalNo placebo

Norway

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lerodalcibep

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Cardiac amyloidosis

Not recruiting

Investigational

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational

Norway

Participants:18–64 years · 65+ years
Substances:Alxn2220

Contact Research Centre

Warm autoimmune haemolytic anaemia+2

Not recruiting

InvestigationalNo placebo

Study on Povetacicept for Patients with Autoimmune Cytopenias (wAIHA, CAD, ITP)

InvestigationalNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Povetacicept

Contact Research Centre

Cold type haemolytic anaemia

Not recruiting

InvestigationalNo placebo

Study on Zanubrutinib for Patients with Primary Cold Agglutinin Disease

InvestigationalNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Zanubrutinib

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Alnuctamab

Contact Research Centre

Idiopathic pulmonary fibrosis

Not recruiting

InvestigationalNo placebo

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Bi 1015550

Contact Research Centre

Splenic marginal zone lymphoma

Not recruiting

Registered drugNo placebo

Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Rituximab

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Investigational

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational

Norway

Participants:18–64 years · 65+ years
Substances:Itepekimab

Contact Research Centre

Find therapies in clinical trials near you – page 46

678 trials match your criteria

Colorectal cancer

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Plasma cell myeloma

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Malignant melanoma+1

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Cardiovascular disorder+1

Study on Long-Term Effects of Lerodalcibep for Lowering Cholesterol in Patients with Familial Hypercholesterolemia or Cardiovascular Disease Risks

Plasma cell myeloma

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Cardiac amyloidosis

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Warm autoimmune haemolytic anaemia+2

Study on Povetacicept for Patients with Autoimmune Cytopenias (wAIHA, CAD, ITP)

Cold type haemolytic anaemia

Study on Zanubrutinib for Patients with Primary Cold Agglutinin Disease

Plasma cell myeloma

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Idiopathic pulmonary fibrosis

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

Splenic marginal zone lymphoma

Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

Chronic obstructive pulmonary disease

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.